The phase III KEYNOTE-671 trial investigating Keytruda, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage 2, 3A or 3B non-small cell lung cancer met its dual primary endpoint of overall survival.
A single-arm, open-label, phase II trial of BXCL701, an oral innate immune activator, in combination with Keytruda (pembrolizumab) in patients with small cell neuroendocrine prostate cancer showed positive overall survival data. As of a data cutoff of Sept. 6, evaluable patients with SCNC showed a median OS of 13.6 months, and a 12-month survival rate of 56.5%.
Results from a phase II study, led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, BC Cancer, and the Canadian Cancer trials Group, suggest that circulating tumor DNA analyses could be used as an early marker of immunotherapy response in advanced non-small cell lung cancer patients and may help guide therapy.
Results from a collaborative study on universal hereditary cancer genetic testing in all patients with breast cancer in a rural population in the Annals of Surgical Oncology. Conducted by Invitae in collaboration with The Outer Banks Hospital in North Carolina from 2019 to 2022, the study analyzed the implementation of universal hereditary cancer genetic testing in all patients with breast cancer, as recommended by the American Society of Breast Surgeons guidelines in 2019.
A study on human tissue and plasma led by researchers at USC Norris Comprehensive Cancer Center shows that their newly developed blood test, OvaPrint, may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.
Research from City of Hope and the Translational Genomics Research Institute, part of City of Hope, suggests that loss of a specific RNA molecule, miR-142, may lead to more aggressive forms of chronic myeloid leukemia.
Scientists at the Translational Genomics Research Institute, part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product-targeting antibody, for the treatment of pancreatic cancer.
A combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a recent study led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center found.
Study data from MAIA Biotechnology, Inc. showed that THIO (6-thio-dG or 6-thio-2’-deoxyguanosine), a first-in-class investigational telomere-targeting agent, demonstrates potent anticancer activity in diffuse intrinsic pontine glioma, one of the most aggressive tumors affecting the central nervous system in children.
The National Comprehensive Cancer Network has released a follow-up survey on the ongoing chemotherapy shortages: 72% of the centers surveyed continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin.